Viking Therapeutics: Pay

Viking Therapeutics paid its 3 named executives $31.6M in total in FY2025 (Dec). CEO Brian Lian, Ph.D. was paid $21.3M of that.

Pay$100 in the stock at the end of FY21 → $765
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Brian Lian, Ph.D.Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years
Marianne ManciniChief Operating Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)Not disclosed
3 years
Greg ZanteChief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 7 peers with pay on file was $14.7M. The CEO of Viking Therapeutics was paid $21.3M, 45% above the median.

  1. 1Viking Therapeutics
  2. 2Madrigal Pharmaceuticals
  3. 3United Therapeutics
  4. 4BridgeBio Pharma
  5. 5Revolution Medicines
  6. 6Protagonist Therapeutics
  7. 7Cytokinetics
  8. 8Krystal Biotech
  9. 9Akero Therapeutics, Inc.Not disclosed
  10. 10Amicus Therapeutics, Inc.Not disclosed
  11. 11Arrowhead Pharmaceuticals, Inc.Not disclosed
  12. 12Avidity Biosciences, Inc.Not disclosed
  13. 13Crinetics Pharmaceuticals, Inc.Not disclosed
  14. 14Dyne Therapeutics, Inc.Not disclosed
  15. 15Intra-Cellular Therapies, Inc.Not disclosed
  16. 16Rhythm PharmaceuticalsNot disclosed
  17. 17SpringWorks Therapeutics, Inc.Not disclosed
  18. 18Summit TherapeuticsNot disclosed
  19. 19VaxcyteNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.